Cargando…

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

INTRODUCTION: In non–small-cell lung cancer, an exon 19 deletion and an L858R point mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to EGFR-tyrosine kinase inhibitors. However, it is uncertain whether other uncommon EGFR mutations are associated with sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Satoshi, Minegishi, Yuji, Yoshizawa, Hirohisa, Maemondo, Makoto, Inoue, Akira, Sugawara, Shunichi, Isobe, Hiroshi, Harada, Masao, Ishii, Yoshiki, Gemma, Akihiko, Hagiwara, Koichi, Kobayashi, Kunihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132025/
https://www.ncbi.nlm.nih.gov/pubmed/24419415
http://dx.doi.org/10.1097/JTO.0000000000000048
_version_ 1782330554175193088
author Watanabe, Satoshi
Minegishi, Yuji
Yoshizawa, Hirohisa
Maemondo, Makoto
Inoue, Akira
Sugawara, Shunichi
Isobe, Hiroshi
Harada, Masao
Ishii, Yoshiki
Gemma, Akihiko
Hagiwara, Koichi
Kobayashi, Kunihiko
author_facet Watanabe, Satoshi
Minegishi, Yuji
Yoshizawa, Hirohisa
Maemondo, Makoto
Inoue, Akira
Sugawara, Shunichi
Isobe, Hiroshi
Harada, Masao
Ishii, Yoshiki
Gemma, Akihiko
Hagiwara, Koichi
Kobayashi, Kunihiko
author_sort Watanabe, Satoshi
collection PubMed
description INTRODUCTION: In non–small-cell lung cancer, an exon 19 deletion and an L858R point mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to EGFR-tyrosine kinase inhibitors. However, it is uncertain whether other uncommon EGFR mutations are associated with sensitivity to EGFR-tyrosine kinase inhibitors. METHODS: A post-hoc analysis to assess prognostic factors was performed with the use of patients with EGFR mutations (exon 19 deletion, L858R, G719X, and L861Q) who were treated with gefitinib in the NEJ002 study, which compared gefitinib with carboplatin-paclitaxel as the first-line therapy. RESULTS: In the NEJ002 study, 225 patients with EGFR mutations received gefitinib at any treatment line. The Cox proportional hazards model indicated that performance status, response to chemotherapy, response to gefitinib, and mutation types were significant prognostic factors. Overall survival (OS) was significantly shorter among patients with uncommon EGFR mutations (G719X or L861Q) compared with OS of those with common EGFR mutations (12 versus 28.4 months; p = 0.002). In the gefitinib group (n = 114), patients with uncommon EGFR mutations had a significantly shorter OS (11.9 versus 29.3 months; p < 0.001). By contrast, OS was similar between patients with uncommon mutations and those with common mutations in the carboplatin-paclitaxel group (n = 111; 22.8 versus 28 months; p = 0.358). CONCLUSIONS: The post-hoc analyses clearly demonstrated shorter survival for gefitinib-treated patients with uncommon EGFR mutations compared with the survival of those with common mutations and suggest that the first-line chemotherapy may be relatively effective for non–small-cell lung cancer with uncommon EGFR mutations.
format Online
Article
Text
id pubmed-4132025
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-41320252014-08-14 Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q Watanabe, Satoshi Minegishi, Yuji Yoshizawa, Hirohisa Maemondo, Makoto Inoue, Akira Sugawara, Shunichi Isobe, Hiroshi Harada, Masao Ishii, Yoshiki Gemma, Akihiko Hagiwara, Koichi Kobayashi, Kunihiko J Thorac Oncol Original Articles INTRODUCTION: In non–small-cell lung cancer, an exon 19 deletion and an L858R point mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to EGFR-tyrosine kinase inhibitors. However, it is uncertain whether other uncommon EGFR mutations are associated with sensitivity to EGFR-tyrosine kinase inhibitors. METHODS: A post-hoc analysis to assess prognostic factors was performed with the use of patients with EGFR mutations (exon 19 deletion, L858R, G719X, and L861Q) who were treated with gefitinib in the NEJ002 study, which compared gefitinib with carboplatin-paclitaxel as the first-line therapy. RESULTS: In the NEJ002 study, 225 patients with EGFR mutations received gefitinib at any treatment line. The Cox proportional hazards model indicated that performance status, response to chemotherapy, response to gefitinib, and mutation types were significant prognostic factors. Overall survival (OS) was significantly shorter among patients with uncommon EGFR mutations (G719X or L861Q) compared with OS of those with common EGFR mutations (12 versus 28.4 months; p = 0.002). In the gefitinib group (n = 114), patients with uncommon EGFR mutations had a significantly shorter OS (11.9 versus 29.3 months; p < 0.001). By contrast, OS was similar between patients with uncommon mutations and those with common mutations in the carboplatin-paclitaxel group (n = 111; 22.8 versus 28 months; p = 0.358). CONCLUSIONS: The post-hoc analyses clearly demonstrated shorter survival for gefitinib-treated patients with uncommon EGFR mutations compared with the survival of those with common mutations and suggest that the first-line chemotherapy may be relatively effective for non–small-cell lung cancer with uncommon EGFR mutations. Lippincott Williams & Wilkins 2014-02 2014-01-23 /pmc/articles/PMC4132025/ /pubmed/24419415 http://dx.doi.org/10.1097/JTO.0000000000000048 Text en Copyright © 2013 by the International Association for the Study of Lung Cancer This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Original Articles
Watanabe, Satoshi
Minegishi, Yuji
Yoshizawa, Hirohisa
Maemondo, Makoto
Inoue, Akira
Sugawara, Shunichi
Isobe, Hiroshi
Harada, Masao
Ishii, Yoshiki
Gemma, Akihiko
Hagiwara, Koichi
Kobayashi, Kunihiko
Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
title Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
title_full Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
title_fullStr Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
title_full_unstemmed Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
title_short Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
title_sort effectiveness of gefitinib against non–small-cell lung cancer with the uncommon egfr mutations g719x and l861q
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132025/
https://www.ncbi.nlm.nih.gov/pubmed/24419415
http://dx.doi.org/10.1097/JTO.0000000000000048
work_keys_str_mv AT watanabesatoshi effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT minegishiyuji effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT yoshizawahirohisa effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT maemondomakoto effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT inoueakira effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT sugawarashunichi effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT isobehiroshi effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT haradamasao effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT ishiiyoshiki effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT gemmaakihiko effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT hagiwarakoichi effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q
AT kobayashikunihiko effectivenessofgefitinibagainstnonsmallcelllungcancerwiththeuncommonegfrmutationsg719xandl861q